Skip to main content
. 2020 Nov 18;2020(11):CD004010. doi: 10.1002/14651858.CD004010.pub4

Comparison 2. Any pessary versus PFMT.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
2.1 Women's perceived improvement of prolapse symptoms at 12 months (measured with PFDI‐20; range: 0‐300, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.2 Women's perceived improvement of prolapse symptoms at 24 months (measured with PFDI‐20; range: 0‐300, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.3 Women's perceived improvement of prolapse symptoms at 12 months (measured with POPDI‐6; range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.4 Women's perceived improvement of prolapse symptoms at 24 months (POPDI‐6; range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.5 Women's perceived improvement of prolapse symptoms at 24 months 1   Risk Ratio (M‐H, Fixed, 95% CI) Totals not selected
2.6 Prolapse‐specific quality of life at 12 months (measured with PFIQ‐7, range: 0‐300, higher score = worse QoL) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.7 Prolapse‐specific quality of life at 24 months (measured with PFIQ‐7, range: 0‐300, higher score = worse QoL) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.8 Quality of life at 12 months (measured with PCS‐12, range: 0‐100, higher score = better health status) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.9 Quality of life at 24 months (measures with PCS‐12, range: 0‐100, higher score = better health status) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.10 Quality of life at 12 months (measured with MCS‐12, range: 0‐100, higher score = better health status) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.11 Quality of life at 24 months (measured with MCS‐12, range: 0‐100, higher score = better health status) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.12 Cure or improvement of bladder problems at 12 months (measured with UDI‐6, range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.13 Cure or improvement of bladder problems at 24 month (measured with UDI‐6, range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.14 Cure or improvement of bowel problems at 12 months (measured with CRADI‐8, range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.15 Cure or improvement of bowel problems at 24 months (measured with CRADI‐8, range: 0‐100, higher score = worse symptoms) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.16 Cure or improvement of sexual problems at 12 months (measured with PISQ‐12, range: 0‐48, higher score = better sexual functioning) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.17 Cure or improvement of sexual problems at 24 months (measured with PISQ‐12, range: 0‐48, higher score = better sexual functioning) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.18 Number of women with adverse events 1 97 Risk Ratio (M‐H, Fixed, 95% CI) 75.25 [4.70, 1205.45]